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ABSTRACT
Androgen deprivation therapy is commonly employed for the treatment of non-
metastatic prostate cancer as primary or adjuvant treatment. The skeleton is greatly 
compromised in men with prostate cancer during androgen deprivation therapy 
because of the lack of androgens and estrogens, which are trophic factors for bone. 
Men receiving androgen deprivation therapy sustain variable degrees of bone loss with 
an increased risk of fragility fractures. Several bone antiresorptive agents have been 
tested in randomized controlled trials in these patients. Oral bisphosphonates, such as 
alendronate and risedronate, and intravenous bisphosphonates, such as pamidronate 
and zoledronic acid, have been shown to increase bone density and decrease the 
risk of fractures in men receiving androgen deprivation therapy.  Denosumab, a fully 
monoclonal antibody that inhibits osteoclastic-mediated bone resorption, is also 
effective in increasing bone mineral density and reducing fracture rates in these 
patients. The assessment of fracture risk, T-score and/or the evaluation of prevalent 
fragility fractures are mandatory for the selection of patients who will benefit from 
antiresorptive therapy. In the future, new agents modulating bone turnover and 
skeletal muscle metabolism will be available for testing in these subjects.
INTRODUCTION
Prostate cancer is the fourth most common cancer 
and the most frequently diagnosed malignancy in men. 
In 2013, there were 1.4 million new cases of prostate 
cancer and 293,000 prostate cancer-related deaths [1], 
with 57% of cases occurring in developed countries, and a 
5-year prevalence of 3,858,000 cases (data source: http://
globocan.iarc.fr/Pages/fact_sheets_cancer.aspx). It is 
estimated that 1 in 7 men will be diagnosed with prostate 
cancer during his lifetime. In Europe, 416.7/100,000 new 
cases of prostate cancer were diagnosed in 2012, with rates 
increasing continuously [2, 3]. Besides being a reflection 
of population aging, much of the increase in the incidence 
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worldwide can be ascribed to prostate-specific antigen 
(PSA) testing and incident detection of prostate cancers 
following trans-uretral resection of the prostate. 
Since the introduction of testing for PSA in the ‘90s, 
a large majority of patients with prostate cancer have been 
diagnosed at early clinical stage [4]. Nonetheless, despite 
the high frequency of low-risk tumors, locally advanced 
and metastatic tumors are still identified at diagnosis [5]. 
Only 40% of patients with high-risk localized tumors 
treated with radical prostatectomy and/or radiotherapy 
remain free of cancer recurrence at 10 years.  In these 
cases, additional surgical or chemical-medical hormone 
deprivation therapy is strongly recommended. Regarding 
metastatic disease, as pointed out by systematic analyses 
of the secular trend of this disease, the pattern of metastasis 
has gradually changed in recent decades, with a decreased 
rate of osseous metastases and increased frequency of non-
osseous ones [6].
Despite the decreasing incidence of advanced 
prostate cancer, studies on prescription databases have 
shown that the use of ADT is increasing since it is now 
frequently employed, outside the guidelines, as an 
adjuvant treatment in early, non-metastatic prostate cancer 
[7]. Moreover, when established early after first-line 
management, this therapy can last for decades [7], putting 
these patients at an increased risk for fragility fractures in 
the long term.
Anti-hormonal therapy is associated with increased 
survival rates in prostate cancer patients. However, 
it is also the reason for long-term side effects, often 
complicated by concomitant comorbidities [5, 8–10]. 
Recently, an association with ADT and increased non-
cancer mortality in older patients with non-metastatic 
prostate cancer has been shown [11].
Cancer-associated bone disease can be the result of 
cancer itself (i.e. malignancy-dependent bone involvement) 
due to tumor-derived circulating bone resorbing molecules 
or metastases and/or anti-hormonal therapies against the 
primary disease (i.e. cancer treatment-dependent bone 
involvement) [12]. In prostate cancer, bone is the main 
target organ for osteoblastic and osteolytic metastases, 
often giving rise to pathologic fractures due to local effects 
[12]. At the same time, anti-hormonal treatment is a major 
cause of bone loss with an increased risk for fragility 
fractures, hampering the quality of life of patients and 
increasing mortality [13, 14]. 
The main drugs proven to be effective in 
postmenopausal and senile osteoporosis have been shown 
to be effective in primary and secondary prevention of 
osteoporosis in prostate cancer, and to decrease the risk of 
fragility fractures [15].
In February 2015, representatives of the 
International Osteoporosis Foundation (IOF) and leading 
experts in the field of prostate cancer convened at a 
meeting in Florence (Italy) to present and discuss the 
existing information on this subject. 
The aim of this document is to specifically address 
the available evidence on cancer-treatment–dependent bone 
disease in non-metastatic prostate cancer and evidence on 
the efficacy and effectiveness of antiosteoporotic treatments 
in these patients, coming from observational, interventional 
and expert consensus, in order to give guidance on this 
subject. Indeed, several scientific societies and working 
groups have approached this argument in the recent past, 
attempting to draw up some guidelines on the monitoring 
and treatment of secondary osteoporosis in cancer patients, 
although no papers were specifically focused on male 
subjects with bone loss secondary to androgen-deprivation 
therapy (ADT) for hormone-sensitive prostate cancer 
[16]. Given these considerations, the management and 
prevention of bone metastases in prostate cancer patients, 
which have been fully addressed in recent publications 
[12], have intentionally been excluded from this paper. 
MATERIALS AND METHODS
A review of the available literature has been carried 
out. Papers were retrieved by means of a PubMed enquiry 
(up to November 2015) using the following terms: “prostate 
cancer”, “epidemiology”, “androgen deprivation therapy” 
and/or “adjuvant therapy” AND “osteoporosis”, “fractures”, 
bone fragility”, “bone remodeling”, “bone turnover”, BMD, 
“skeletal homeostasis”, “bone metabolism”, “fracture 
risk assessment”, FRAX”, “muscle”, “sarcopenia”, 
“antiresorptives”, “bisphosphonates”, or active principle 
of bisphosphonates (such as pamidronate, alendronate, 
risedronate, zoledronate), “denosumab”, “calcium”, 
“vitamin D”, “cost effectiveness analysis”. International 
guidelines from Cancer and Bone Societies and have been 
taken into account and integrated.  Data were retrieved, 
summarized, and incorporated in order to provide an 
objective, complete description of the available evidence. 
Finally, main review articles on the subject were retrieved 
and appropriately cited.
Androgen deprivation therapy (ADT) in prostate 
cancer
Prostate cells are physiological targets for androgens, 
which stimulate their function, growth, and proliferation 
[17]. Indeed, testosterone, although not tumorigenic 
itself, promotes the growth, proliferation and propagation 
of androgen-sensitive tumor cells. Conversely, prostate 
cells deprived of androgenic stimulus undergo apoptosis 
[18]. ADT refers to any treatment eventually resulting in 
the suppression of androgen activity [19]. ADT can be 
attained both by suppressing the secretion of testicular 
androgens (by means of bilateral orchiectomy or long 
acting GnRH agonists or antagonists) or by inhibiting the 
action of circulating androgens at the level of their receptor 
using competing compounds (by means of non-steroidal 
antiandrogens or steroidal antiandrogens). In addition, 
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these two therapeutic approaches can be used together to 
reach the complete, also referred to as maximal or total, 
androgen blockade (CAB) [20].
Surgical castration, the best option to realize ADT, 
leads to a substantial decrease of testosterone levels, i.e. 
below 20 ng/dl (or 1 nmol/L). However, the definition 
of castration level obtained with medical ADT and 
considered by regulatory authorities for disease control is 
a serum testosterone below 50 ng/dl (or 1.7 nmol/L) [20].
Long-acting LHRH agonists (such as goserelin, 
leuprolide, triptorelin) are currently the most commonly 
employed drugs in ADT. Chronic exposure to LHRH 
agonists results in the desensitization of LHRH-receptors, 
suppressing LH and FSH secretion and, consequently, 
testosterone production. Castration level is usually 
obtained within 2–4 weeks. LHRH antagonists, such as 
degarelix, reduce testosterone levels more rapidly and 
do not cause flare-up phenomena, as LHRH agonists do 
at the beginning of therapy due to transient stimulation 
of FSH and LH and consequent testosterone surge. 
These compounds can be administered either alone or in 
combination with androgen receptor antagonists, such as 
flutamide, nilutamide, or bucalutamide, in order to reach 
CAB [21]. Two additional compounds, abiraterone acetate 
and enzalutamide, targeting the androgen axis, have 
recently been developed in order to blunt the effects of 
intracellular androgens, which are increased in castration-
resistant prostate cancer [22].
ADT is considered the gold standard therapy for 
locally advanced or metastatic androgen-dependent 
prostate cancer in order to support long-term benefits, 
according to several international guidelines [20, 21]. 
There are many issues around anti-hormonal 
therapy, such as treatment of early stage prostate cancer, 
the best time to start (immediate vs deferred), and the best 
means of administration (partial vs maximal blockade, 
intermittent vs continuous). Indeed, adverse effects of life-
long androgen deprivation may be avoided in a substantial 
number of patients with a deferred treatment policy [5].
To date, ADT is indicated for symptomatic patients 
with metastatic disease, or extensive T3-T4 histological 
staging, or high PSA level (> 50 ng/ml) or (> 25 ng/mL 
and PSA doubling time < 1 year), and in the case of at 
least 2 positive lymph nodes after extended lymph node 
dissection [21, 23]. Conversely, ADT is not usually 
advised for early stage prostate cancer due to a lack of 
evidence of long-term benefits [4].
ADT has also been employed as adjuvant therapy 
in place of radiotherapy before prostatectomy in the case 
of locally advanced tumors with negative lymph nodes, 
in asymptomatic patients with metastasis, or in men 
with localized prostate cancer who are unfit for surgery 
or radiation. However, in these latter cases, no sufficient 
evidence deriving from properly conducted randomized 
controlled trials (RCTs) for a beneficial ADT-mediated 
effect on disease-free survival, local disease control, or 
mortality rate, has been demonstrated with respect to non-
active surveillance or other therapies [20, 21]. Continued 
testicular androgen suppression with LHRH analogues in 
CRPC is debatable. However, in the absence of prospective 
data, the modest potential benefits of a continuing 
castration outweigh the minimal risk of treatment [21, 24].
Once medical ADT is established, soon after first-
line management, it can last decades, as demonstrated by 
analyses of prescription patterns of antiandrogens in men 
diagnosed with localized prostate cancer [7]. On the other 
hand, the use of ADT both by academic and non-academic 
urologists has gradually decreased in some countries, 
such as the USA, perhaps reflecting reimbursement cuts 
in recent years, or the awareness of potentially serious 
adverse effects [25].
Osteoporosis in patients with prostate cancer
Mechanisms of bone loss during ADT
ADT in prostate cancer patients reduces serum 
testosterone levels to the castration range (< 5% of the 
normal range) and serum estradiol levels to < 20% of the 
normal level [26]. The importance of sex steroids, mainly 
estrogen, for the maintenance of bone mass in adult and 
elderly men has been established by numerous cross-
sectional and prospective observational studies showing 
a strong association between serum levels of total and 
bioavailable estradiol (E2) with BMD and BMD loss 
[27–31] (Figure 1). From a molecular point of view, 
the key mechanism involved is the upregulation of 
the receptor activator of NF-κB ligand (RANKL) and 
downregulation of osteoprotegerin induced by estrogen 
loss, which enhances osteoclast recruitment and activation 
leading to bone loss [26ì7].
In a cohort of elderly men from Rochester, Minnesota, 
a threshold for bone loss was found at a bioavailable E2 level 
of 11 pg/mL (total E2 31 pg/ml) [30]. A similar threshold 
below which bone loss accelerated at the lumbar spine 
and femoral neck was reported in other studies [31, 32]. 
Intervention studies also strongly indicate that estrogen 
deficiency is the primary mediator of bone loss [33, 34]. 
Furthermore, low estrogen levels in hypogonadal males 
are strongly associated, at least in part, in an independent 
manner, to fracture risk. Several large-scale prospective 
studies found a relationship between total and bioavailable 
estrogen levels and fracture incidence with an E2 threshold 
of 16 and 12 pg/ml, respectively [34, 35]. The contribution 
of serum testosterone (T) to BMD, bone turnover and 
fracture risk in hypogonadal men is more complex than 
that of E2 (Figure 1). Serum T levels have moderate effects 
on fracture risk and seem to be associated with effects on 
bone formation, cortical area and extraskeletal factors, such 
as muscle mass, strength and risk of falls [27]. Sarcopenia 
and increase in body fat occur as early as 3–6 months 
after beginning ADT. A mean increase of 7.7% in body 
fat and about 3% mean reduction in lean body mass have 
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been reported [36]. Bone and skeletal muscle constitute 
a highly integrated system, and sarcopenia is associated 
with fractures, not only by increasing the risk of fall, but 
also by reducing BMD and impairing bone geometry and 
microstructure [37, 38]. Furthermore, sex steroids may 
influence local IGF signaling in bone and have an indirect 
effect on bone via the GH/IGF-1 axis. Low IGF-1 was 
found to be associated with fracture risk in older men, 
but no association was found with sex steroids. These 
relationships should be further investigated [39] (Figure 2).
Epidemiology of osteoporosis and fragility 
fractures during ADT
Since ADT is started in almost 50% of men with 
prostate cancer at some point after diagnosis, and most will 
take it for at least 2 to 3 years, there is an increasing number 
of these patients living with severe hypogonadism [40, 19].
Major adverse effects of ADT are consequences 
of induced hypogonadism that include fatigue, sexual 
dysfunction, increased fat mass, sarcopenia, and osteoporosis 
with fragility fractures [41].  It is well known that 
ADT induces high bone turnover and, consequently, a 
significantly high rate of bone loss, 4–4.6 % annually, 
which significantly exceeds that of aging male and 
postmenopausal women, and is about two-fold that of 
women with breast cancer treated with aromatase inhibitors 
[42, 43]. The prevalence of osteoporosis or osteopenia in 
prostate cancer patients on ADT seems to be very high, 
with the majority experiencing poor bone health (up to 
85%) [44], with variation of prevalence for osteoporosis 
among the studies (from 9.0 to 53%) influenced by ADT 
duration, disease stage, ethnicity, and skeletal site of DXA 
scan [44, 45].  It is noteworthy that the prevalence of 
osteoporosis in ADT-naive prostate cancer patients is about 
4–38%, and men with more advanced disease at diagnosis 
display a higher prevalence of osteoporosis; therefore, ADT 
may worsen pre-existent osteoporosis [46–48]. Bone loss 
seems to be maximal in the first years after the initiation 
of ADT, ranging from 1.5% to 4.0%, depending on the 
skeletal site measured [43, 46].
A number of epidemiological studies have associated 
ADT with an increased risk of fractures. The association 
between ADT and fractures derived from studies including 
Figure 1: Effects of sex steroids on bone. Androgens like T can be converted via aromatization to estrogens and can thus activate 
both AR and ERα. In males, both AR and ERα maintain cortical and trabecular bone in adult male. Estrogens increases osteoblast number 
and activity, inhibit osteocyte apoptosis, reduces the number and activity of osteoclasts. Androgen directly increase number and function 
of osteoblasts and inhibit apoptosis of osteocytes. Osteoclasts apparently do not express AR. Trabecular bone formation is increased by 
ERα in males, whereas both ERα and AR can inhibit trabecular bone resorption. ERα inhibits endosteal bone resorption and with GH/
IGF-1 (probably via central aromatization of androgens) stimulates periosteal bone formation). The action of GH/IGF-1 axis in particularly 
evident during puberty. E2 : estradiol; T: testosterone; DHT dihydrotestosterone; Era: estrogen a-receptor; AR: androgen receptor; OB: 
osteoblast; OC osteocyte; OCL :osteoclast; GH: growth hormone; IGF-1: insulin growth-factor;.
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more than 100.000 men was systematically reviewed, and 
a summary RR of 1.23 (95% CI, 1.10–1.38) for skeletal 
fracture and RR 1.39 (95% CI ,1.20–1.60) for vertebral 
fracture was found  [41]. Men with a high baseline risk 
of skeletal complications develop more fractures after 
ADT [49]. The fracture rate increased by 19.9 per 1000 
person-years (from 52.9 to 73.0 person –years) in men 
who received 18 or more doses of ADT [49].  As recently 
demonstrated, patients who received CAB with GnRH 
agonists and antiandrogens have a higher fracture risk 
than those who received monotherapy [50]. Mortality after 
fragility fracture is higher in men, with age-standardized 
mortality ratios of 2.2–3.2 compared with 1.7–2.2 in 
women [51]. Men with prostate cancer experiencing a 
fracture had a 1.38-fold higher overall mortality risk than 
those who did not (95% CI, 1.34–1.43) [49, 52].
State-of-the-art in the therapy of osteoporosis in 
patients affected by prostate cancer
Several RCTs have proven the efficacy of 
antiresorbing and bone-formative agents commonly 
employed in men with idiopathic or age-related osteoporosis 
[53, 54] (Table 1A).
In men without prostate cancer, these therapies 
lead to a net increase in BMD, but there is little evidence 
for their efficacy in decreasing fracture risk [53]. In 
men, alendronate, zoledronic acid, and teriparatide have 
been shown to decrease the occurrence of new vertebral 
fractures [54–58], while for risedronate no significant 
effect on fractures was observed, likely due to the small 
number of fractures [59]. In males after a hip fracture, i.v. 
zoledronic acid 5 mg once a year has been shown to be 
effective in reducing the risk of further fractures while 
improving survival [60]. In males with a BMD T-score 
between -2 and -3.5 SD or with previous fragility fractures 
and BMD T-score between -1 and -3.5 (ADAMO trial), 
the fully human monoclonal antibody against receptor 
activator of nuclear factor-kB ligand (RANKL), i.e. 
denosumab 60 mg, administered subcutaneously every 
6 months, significantly increased lumbar spine and total 
hip BMD (by 5.7% and 2.4%, respectively at one year) 
by directly inhibiting bone resorption, with changes in 
BMD independent of testosterone levels [61]. Although 
no data on fracture prevention in men with idiopathic 
osteoporosis are available, denosumab has been confirmed 
to be effective and safe in significantly increasing BMD at 
trabecular and cortical sites [62].
Recently, a meta-analysis has compared the effects 
on BMD at the lumbar spine and the fracture rate in 
men among different antiosteoporotic compounds, not 
including denosumab [63]. The greatest positive change in 
BMD was observed for zoledronic acid, while teriparatide 
was ranked first for reducing fracture rate [63].
Alendronate, risedronate, zoledronic acid, teriparatide 
and denosumab are currently approved for the treatment 
of male osteoporosis, while strontium ranelate is approved 
only in Europe, with some restrictions [64] (Table 1A).
Besides the anabolic teriparatide, which cannot be 
recommended for patients with prostate cancer at risk for 
osseous metastases, bisphosphonates and denosumab can 
be employed for the treatment of secondary osteoporosis 
in men due to ADT. The fact that these antiresorptive 
drugs have also been proposed to prevent or delay cancer-
induced bone disease (i.e. to prevent skeletal related events 
in CRCP treated with long-term ADT), mainly for their 
ability to render bone microenvironment unsuitable for 
cancer cell nesting and implantation, has already been the 
subject of extensive reviews [65, 66]. Herein, the specific 
efficacy of antiresorptive drugs in increasing BMD and 
preventing fragility fractures in non-metastatic, hormone-
sensitive prostate cancer patients will be presented.
Parenteral and oral bisphosphonates have been 
shown to be effective in preventing ADT-induced bone, or 
increasing lumbar spine and hip BMD, although data on the 
effect on fracture rate are lacking [67] (Table 1B and 1C). 
The evidence from studies in men with non-metastatic 
prostate cancer is described below and further detailed in 
Table 1B.
Pamidronate was the first bisphosphonate to be tested 
in a RCT as a preventive therapy for ADT-induced bone 
loss [70]. In this 48-week-long study, 47 men receiving 
leuprolide (a gonadotropin releasing hormone agonist) 
for non-metastatic, but locally advanced, lymph node-
positive, or recurrent prostate cancer, were randomized to 
receive pamidronate 60 mg intravenously every 12 weeks. 
This treatment was proven to be significantly effective in 
preventing the reduction in BMD at the hip (p < 0.005) 
and lumbar spine (p < 0.0001) provoked by ADT therapy, 
compared to the placebo-treated group. Indeed, trabecular 
BMD decreased by 8.5% in men receiving leuprolide 
alone, whereas it did not change in the leuprolide-
pamidronate treated group, in which a marked modification 
of bone turnover markers was also demonstrated [70].
After the FDA approval of zoledronic acid 4 mg 
for the treatment of hypercalcemia of malignancy, several 
studies tested this potent amino-bisphosphonate in bone 
diseases because of its substantial effects on the skeleton. 
Several RCTs began to examine its potential action in 
contrasting ADT-induced bone loss (as reviewed in 67). The 
first randomized trial of this series tested intravenous (i.v.) 
zoledronic acid (4 mg/3 monthly) against placebo in men 
with non-metastatic prostate cancer at the start of treatment 
with ADT [71]. Mean lumbar spine and total hip BMD 
increased by 7.8% and 3.9%, respectively, after one year of 
treatment with zoledronic acid, whereas BMD decreased in 
the group receiving placebo. In addition, the rise in BMD 
occurred irrespective of the ADT regimen employed [71]. 
Comparable results were confirmed in similar studies, 
in which zoledronic acid was also shown to be effective 
in reducing bone turnover, and well tolerated [72–75], 
even when administered in a single annual dose [76]. 
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Table 1: Randomized placebo-controlled studies demonstrating the efficacy of antiresorptive 
agents currently approved for the treatment of male osteoporosis (*with the exception of strontium 
ranelate, which have been approved only in Europe with some restrictions): effect in increasing 
BMD and preventing fragility fractures in men with osteoporosis and without prostate cancer, 
and in men with prostate cancer with or without bone metastases
1a. Male osteoporosis
Study Treatment 
period
Patients Drug tested in 
the treatment 
group
Drug regimen Increase in BMD Reduction of 
fracture risk
Orwoll et al. [55] 24 months n. 241 men with osteoporosis alendronate 10 mg/day, oral Yes (spine and hip) Yes (vertebral)
Boonen et al. [59] 24 months n. 284 men with osteoporosis risedronate 35 mg/week, 
oral
Yes (spine and hip) No
Boonen et al. [56] 24 months n. 1199 men with primary or 
hypogonadal osteoporosis
zoledronate 5 mg/year, i.v. Yes (spine and hip) Yes (vertebral)
Orwoll et al. [57]
Kaufman et al. [58]
Premature 
termination 
(median 
exposure: 11 
months)
n. 437 men with primary or 
hypogonadal osteoporosis
teriparatide 20 or 40 mcg/
day, s.c.
Yes (spine and hip) Yes (vertebral)
Lyles et al. [60] 24 months n. 508 men with hip fracture zoledronate 5 mg/year, i.v. Yes (spine and hip) Yes (vertebral 
and non-
vertebral)
Orwoll et al. [61] 12 months n. 242 with low BMD denosumab 60 mg/6 
months, s.c.
Yes (spine, hip and 
radius)
No
Kaufman et al. [64] 24 months n. 261 with osteoporosis strontium 
ranelate*
2 g/day, oral Yes (spine and hip) No
1b. Men with prostate cancer without bone metastases (M0) under ADT
Study Treatment 
period
Patients Drug tested in 
the treatment 
group
Drug regimen Prevention 
of reduction/
increase in BMD
Reduction of 
fracture risk
Smith et al. [70] 48 weeks n. 47 men with locally 
advanced, lymph-node positive 
or recurrent prostate cancer 
(M0) starting ADT (leuprolide)
pamidronate 60 mg/12 
weeks, i.v.
Yes (spine and hip) No
Greenspan et al. [80]
Greenspan et al. [81]
12–24 months n. 112 men with prostate cancer 
(M0) on ADT (GnRH agonists 
or antiandrogen or combination 
therapy)
alendronate 70 mg/week, 
oral
Yes (spine and hip) No
Klotz et al. [82] 12 months n. 191 men with prostate 
cancer (M0) starting ADT 
(leuprolide acetate)
alendronate 70 mg/week, 
oral
Yes (spine and hip) No
Choo et al. [85] 24 months n. with locally advanced 
prostate cancer (N0 M0)
risedronate 35 mg/week, 
oral
Yes (spine and hip) No
Smith et al. [71] 12 months n. 106 men with prostate 
cancer (M0), beginning ADT 
(GnRH analog with or without 
antiandrogen)
zoledronate 4 mg/3 months, 
i.v.
Yes (spine and hip) No
Israeli et al. [73] 48 weeks n. 215 men with locally 
advanced prostate cancer (M0) 
on ADT (LHRH agonist with 
or without antiandrogen) for 
< 12 months
zoledronate 4 mg/3 months 
i.v.
Yes (spine and hip) No
Kapoor et al. [75] 12 months n. 41 men with prostate cancer 
(M0) on ADT (LHRH agonist 
or orchidectomy) for < 12 
months
zoledronate 4 mg/3 months 
i.v.
Yes (spine and hip) No
Bhoopalam et al. [74] 12 months n. 93 men with prostate cancer 
(M0) on or starting ADT 
(LHRH agonist with or without 
antiandrogen or orchiectomy)
zoledronate 4 mg/3 months 
i.v.
Yes (spine and hip) No
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The latter RCTs demonstrated that zoledronic acid is 
effective in preventing ADT-induced bone loss even 
when administered less frequently, regardless of baseline 
BMD and ADT regimen. Few RCTs have demonstrated 
zoledronic acid efficacy in preserving or increasing BMD 
when employed for a period of time longer than one year 
(up to 36 months) [77, 78], or even when started later in the 
course of ADT (i.e. more than 1 year) [74]. However, even 
in the study with the longest follow-up, no difference in 
incident vertebral fractures was found, despite the positive 
effect on BMD [78].
The optimal regimen for zoledronic acid in patients 
receiving ADT has yet to be established. Nonetheless, in 
a prospective open-label study, no difference in the gain 
in BMD was noted between groups receiving zoledronic 
acid 4 mg monthly, bi-monthly, tri-monthly or every six 
months [79].
It is worth noting that in all these trials performed in 
patients receiving ADT over the last 15 years, zoledronic 
acid was employed at the 4 mg dose and not at the 5 
mg yearly dose, which is approved for the treatment of 
idiopathic osteoporosis. 
In addition to parenteral bisphosphonates, oral 
bisphosphonates, such as alendronate (at the dose of 70 mg 
weekly) and risedronate (at a dose of 2.5 mg daily or 35 mg 
weekly) have been tested in RCTs in men receiving ADT, 
and were shown to be well tolerated overall and effective 
in preserving or increasing BMD at trabecular and cortical 
sites, while decreasing bone turnover markers [80–85]. 
In a meta-analysis including data on BMD, rate of 
fractures, and adverse events from 15 RCTs performed in 
men receiving ADT for prostate cancer, with or without 
bone metastases, bisphosphonate therapy had a marked 
effect in preventing osteoporosis, but also fractures (risk 
ratio 0.39, p < 0.00001 and 0.80, p = 0.005, respectively) 
[86]. Therefore, this study confirmed that bisphosphonates 
are effective in preserving and preventing bone loss 
and fractures occurring receiving ADT. Moreover, 
zoledronate appeared to be more effective than the other 
bisphosphonates in preventing fractures [86]. 
As demonstrated in a recent retrospective analysis of 
administrative databases, however, despite the increased 
knowledge of ADT-mediated bone loss and evidence 
of the efficacy of bisphosphonates, the prescriptions of 
these drugs in hypogonadal prostate cancer patients have 
remained overall low in the last decade, even in those at 
high risk for fractures [87].
Besides bisphosphonates, the efficacy of the 
antiresorptive agent denosumab was tested in men 
receiving ADT even before being assessed in men with 
idiopathic osteoporosis, after the initial experience in 
women receiving aromatase inhibitors for hormone-
sensitive breast cancer. In the multicenter, double-blind, 
placebo-controlled study by Smith et al. (HALT study), 
Michaelson et al. [76] 12 months n. 40 men with prostate cancer 
(M0) receiving GnRH analogs 
and with T-score > –2.5
zoledronate 4 mg/year i.v. Yes (spine and hip) No
Casey et al. [77] 24 months n. 200 men with prostate 
cancer (M0) starting ADT 
 (< 30 days of goserelin 
acetate)
zoledronate 4 mg/3 months 
i.v.
Yes (spine and hip) No
Denham et al. [78] 36 months n. 1071 men with locally 
advanced prostate cancer (M0) 
starting ADT (leuprorelin)
zoledronate 4 mg/3 months 
i.v.
Yes (spine and hip) No
Smith et al. [88] 36 months n. 1468 men with prostate 
cancer (M0) on ADT (GnRH 
agonist or orchiectomy)
denosumab 60 mg/6 months 
s.c.
Yes (spine and hip) Yes (vertebral)
1c. Men with prostate cancer with bone metastases (M1) under ADT
Study Treatment 
period
Patients Drug tested in 
the treatment 
group
Drug regimen Increase in BMD Reduction of 
fracture risk
Diamond et al. [68] 6 months n. 21 with metastatic prostate 
cancer (M1) on ADT (goserelin 
with antiandrogen for > 6 
months)
pamidronate 90 mg single 
dose i.v.
Yes (spine and hip) No
Ryan et al. [72] 12 months n. 42 with non-metastatic 
and metastatic prostate 
cancer (M0 and M1) on ADT 
(orchidectomy or LHRH 
agonist for < 12 months)
zoledronate 4 mg/3 months 
i.v.
Yes (spine and hip) No
Satoh et al. [69] 12 months n. 40 men with metastatic 
prostate cancer (M1) starting 
ADT (GnRH agonist)
zoledronate 4 mg/year i.v. Yes (spine and hip) No
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1468 men receiving ADT for non-metastatic, hormone-
sensitive prostate cancer, the majority of whom (i.e. 
77.9%) had T-score <-1.0 and receiving ADT for more 
than 6 months, were randomized to receive denosumab 
(60 mg subcutaneously) or placebo every 6 months, for up 
to 36 months [88]. The change in lumbar spine BMD at 24 
months was set as the primary end point, while the change 
in total hip BMD at 24 and 36 months and the incidence of 
newly diagnosed vertebral fractures were set as secondary 
end points. Lumbar spine BMD increased by 5.6% in the 
denosumab-treated group and decreased by 1% in the 
placebo-treated group, with a significant 6.6 difference 
in percentage points between the two groups. Significant 
changes in BMD at the total hip, femoral neck and distal 
third of the radius were also observed at 24 months, with 
a difference in percentage points between groups of 4.8, 
3.9 and 5.5, respectively. Positive changes in BMD in the 
denosumab-treated patients were observed independently 
of baseline T-score levels and prevalent vertebral fractures. 
In the group of men receiving ADT receiving denosumab, a 
striking decrease in the rate of new vertebral fractures was 
observed, namely a 62% reduction, at 36 months (1.5% in 
the denosumab-treated versus 3.9% in the placebo-treated, 
with a relative risk of 0.38, confidence interval 0.19.0.78, 
p < 0.006), with no difference in the rate of adverse events 
even in the long term [88]. The magnitude of the effect of 
denosumab treatment on fracture rate is indeed similar to 
that demonstrated in the FREEDOM trial in women with 
postmenopausal osteoporosis receiving the same drug 
regimen [89]. The gain in BMD and the rapid marked 
reduction in the rate of bone turnover in men receiving 
ADT was similar to that observed in the FREEDOM 
and ADAMO trials [88, 89, 61]. In subgroup analyses of 
subjects participating in the HALT study, no difference was 
Figure 2: Mechanisms of bone loss in men with prostate cancer receiving androgen deprivation therapy. Androgen 
deprivation therapy reduces testosterone levels and indirectly the estrogen levels in man.  The low serum and tissue levels of estrogen 
increase  bone turnover increasing  the number of BMU and increasing the  number of osteoclasts. The low levels of estrogen increase 
endosteal reabsorption and cortical porosity. Androgen and estrogen deficiency reduces the thickness and the number of trabeculae and high 
bone turnover reduce trabecular connectivity, predisposing to bone fragility. Sarcopenia increases risk of falls and indirectly impairs bone 
metabolism. E2 : estradiol; T: testosterone; DHT dihydrotestosterone; Era: estrogen a-receptor; AR: androgen receptor; OB: osteoblast; OC 
osteocyte; OCL :osteoclast; GH: growth hormone; IGF-1: insulin growth-factor; ADT: Androgen deprivation therapy; Dotted-line: lack of 
action
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observed in terms of gain in BMD with respect to different 
baseline variables such as BMI, age, prevalent fractures, 
BMD and bone turnover markers, and prior duration/
regimen of ADT [90].
Several studies on cost-effectiveness of 
antiresorptive agents in the prevention of osteoporotic 
fractures have demonstrated that these drugs are cost-
effective or even cost-saving when administered to subjects 
aged 50 years or older with a risk for fractures above a 
certain threshold, e.g 20% as established by the FRAX 
algorithm [91]. Unfortunately, only one cost-effectiveness 
analysis of this kind has been performed, and only for 
alendronate in men receiving ADT [92]. This study showed 
that a BMD assessment, followed by proper therapy with 
alendronate for 5 years in the case of osteoporosis (as 
defined by T-score), was cost-effective when performed 
in men aged 70 years, with locally advanced or high-
risk localized prostate cancer starting a 2-year course of 
ADT after radiotherapy. On the other hand, administering 
alendronate without a BMD is cost-effective when 
administered to older men with history of fractures or with 
a history of lower BMD prior to ADT [92].
Recent trials have investigated the efficacy 
of antiresorptives as a preventive measure for the 
development of bone metastases in patients with prostate 
cancer. In the European Zometa Study (ZEUS) performed 
in 1433 selected patients with non-metastatic, high-risk 
localized prostate cancer, zoledronate failed to increase 
bone-metastases-free survival rates [93]. These results 
were confirmed in the RADAR trial, in which zoledronate 
did not offer a clear benefit in this regard [78]. By contrast, 
denosumab has recently been shown to significantly delay, 
by a median of 4.1 months, the onset of bone metastases 
in a study involving 1432 subjects with castration-
resistant, non-metastatic prostate cancer [94]. It is likely 
that high-risk patient subgroups would benefit more from 
antiresorptive therapy in this respect. Indeed, a subgroup 
analysis has shown that patients with a shorter doubling 
time of PSA were likely to benefit more from denosumab 
administration in terms of bone metastases prevention 
[95]. However, no positive effects on overall survival 
rates have been observed in the denosumab-treated group. 
Moreover, a high incidence of osteonecrosis of the jaw 
was observed in the denosumab-treated group [94]. For 
these reasons, denosumab has not been approved for the 
prevention of bone metastases in men with prostate cancer 
and without bone metastases.
Fracture risk assessment in prostate cancer 
patients receiving ADT and preventive measures
Osteoporosis and the risk of fragility fractures 
should be assessed in all patients with prostate cancer, and, 
in particular, in those starting or receiving ADT.
After carefully reviewing the medical history and a 
focused physical examination, the risk for fractures should 
be estimated by looking at bone mineral density (BMD) 
by dual energy X-ray absorptiometry (by DXA), and by 
assessing vertebral prevalent fractures (by X-ray or by 
DXA) [16] (Figure 3). Low BMD values (i.e. T-score < 
–2.5 at the total hip, femoral neck or lumbar spine) indicate 
the need to start appropriate antiresorptive therapy. Since a 
similar fracture risk has been observed for the same DXA-
derived BMD values in men and women, the use of a large 
Caucasian female referent database for the calculation of 
T-score in men has been agreed upon [96]. Consequently, 
a greater proportion of men will experience a fracture at 
higher T-score values. For this reason, it is necessary not to 
rely only on the T-score for the selection of men who will 
receive/take advantage of an antiosteoporotic treatment [97]. 
In addition to BMD, clinical risk factors have to be taken 
into account for the diagnosis of osteoporosis. Therefore, 
the presence of a fragility fracture is sufficient criterion to 
diagnose osteoporosis, independent of T-score values. In 
addition to the detection of prevalent fragility fractures, the 
FRAX algorithm calculated using femoral BMD is a good 
tool for assessing overall fracture risk, considering “ADT 
therapy” as secondary osteoporosis [16, 97]. The FRAX 
computer-based algorithm is a tool that has been specifically 
developed to estimate fracture risk of patients of both sexes. 
The FRAX-estimated risk comes from the simultaneous 
assessment of multiple individual clinical risk factors 
and may include BMD at the femoral neck for further 
refinement of the 10-year probability of major osteoporotic 
fractures or hip fractures [98]. Nonetheless, whether FRAX-
derived fracture probability fits ADT risk has not been 
established; consequently, a FRAX intervention threshold 
specific for these patients requires validation. Regarding 
postmenopausal osteoporosis, in the past, some guidelines 
recommended a 20% intervention threshold for a major 
osteoporotic fracture and a 3% threshold for a hip fracture. 
Although these recommendations were based on health 
economic considerations relevant to the US many years ago, 
they have been advocated by many authorities, given that 
they were originally selected by the National Osteoporosis 
Foundation [99]. Recently, age-dependent thresholds 
have been validated and adopted for both sexes, first in 
the United Kingdom [98], then in more than 30 countries, 
including the European Guidelines [100, 101]. There are 
noticeable differences in intervention thresholds between 
countries, because of differing population risks of fracture 
and death, especially at younger ages. Those recommended 
for Western Europe are shown in Figure 4.
Recently, the FRAX algorithm has also been 
demonstrated to predict falls in elderly males [102]. This is 
of pivotal importance for the evaluation of men receiving 
ADT, since loss of androgens could also compromise 
muscle mass and function, therefore increasing the rate 
of fall and hindering the rehabilitation process after major 
fragility fractures.
If a diagnosis of osteoporosis is made according to 
the above criteria, first-line diagnostic tests must always 
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be undertaken in order to exclude secondary causes of 
osteoporosis (Figure 3). The assessment of bone turnover 
markers is controversial, although it may be useful for 
monitoring treatment. 
General recommendations for bone health in 
patients with non-metastatic prostate cancer
Patients with prostate cancer, and above all those 
starting or receiving ADT, should have some preventive 
measures not different from those used for primary 
prevention of idiopathic osteoporosis (i.e. physical exercise, 
nutrition, optimal lifestyle, vitamin D supplementation), 
independent of further bone assessments [16] (Figure 3). 
It is advisable to test vitamin D status and check daily 
calcium intake by means of questionnaires in all patients 
with prostate cancer in order to provide proper supplements 
and/or appropriate nutrition advice. According to the 
National Comprehensive Cancer Network’s guidelines on 
prostate cancer, levels of serum 25(OH)D, a marker for 
vitamin D status, should be checked and maintained at 
least above 20 ng/ml (i.e. 50 nmol/L) by means of a daily 
intake of ≥ 800 IU of cholecalciferol, together with a daily 
calcium intake of 1000 mg, by means of calcium-rich foods 
or supplements. The maintenance of a positive calcium 
balance is mandatory in the case of concomitant therapy 
with intravenous bisphosphonates or denosumab, because 
of the risk of hypocalcemia [16].
Several evidence-based practical guidelines for 
the management of secondary osteoporosis in men with 
prostate cancer receiving anti-hormonal treatments have 
been issued [16, 103].
Combining the recommendation from the US-based 
National Osteoporosis Foundation and Osteoporosis 
Canada, the IOF experts have agreed that individuals 
with osteoporosis (T-score a -2.5), and/or with a risk 
assessed by FRAX exceeding 20% for major fractures, 
or 3% for hip fractures, and/or displaying vertebral 
fragility fractures, should be treated with antiresorptives 
[16] (Figure 3). Nonetheless, IOF experts acknowledge 
that these indications can be adapted in different regions/
countries according to expert guidance and insurance 
reimbursement policies [16].
Although the optimal regimen and long-term 
effects of antiresorptives must be established, they are 
recommended in the above-mentioned conditions, since 
Figure 3: IOF’s algorithm for the management of non-metastatic bone disease in prostate cancer patients receiving 
ADT (modified from ref. 16).
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they are capable of decreasing ADT-mediated bone loss 
in at-risk individuals. Oral bisphosphonates, such as 
weekly alendronate or risedronate, zoledronic acid (5 mg) 
administered once yearly, or denosumab 60 mg dispensed 
subcutaneously every 6 months, are the treatments of 
choice. In the selection of antiresorptive therapy, the 
problem of low adherence to oral bisphosphonates leading 
to early treatment discontinuation has to be taken into 
account. For this reason, drugs such as zoledronic acid and 
denosumab administered parenterally at wider intervals 
might be preferred.
In high-risk patients placed on antiresorptives, as 
well as low-risk patients managed conservatively, BMD 
should be monitored by DXA every 18–24 months. Men 
receiving ADT with T-score between -1 and -2.5 followed-
up without antiresorptive should have BMD measured 
every 12 months in order to detect small significant 
changes, particularly at sites rich in cancellous bone (i.e. 
lumbar spine) placing them in the high-risk category [16]. 
To date, no evidence-based recommendations can 
be made on the possible administration of antiresorptives 
such as denosumab as a preventive measure for bone 
metastases or pathologic fractures in men receiving ADT 
for non-metastatic prostate cancer, due to significant side 
effects and poor evidence of oncologic benefit. 
Research agenda
Several issues need to be addressed in the near 
future for the maintenance or improvement of bone health 
in patients treated with ADT for prostate cancer.
The efficacy in terms of BMD gain and fracture risk 
reduction of emerging therapies targeting skeletal muscle 
besides bisphosphonates and denosumab needs to be 
tested in RCTs in men receiving ADT (Table 2). 
Estrogens have been shown to be important for bone 
health in men as well as in women. Since estrogens in 
men derive from the peripheral conversion of testosterone, 
ADT reduces estrogen levels in parallel to testosterone. 
Therefore, it is conceivable that increasing their levels 
in men receiving ADT could be beneficial to bone mass. 
One study has addressed this issue assessing the effect of 
a therapy with estradiol on bone density in a small number 
of men receiving ADT [104]. No significant changes in 
BMD were observed as a consequence of administration 
of estradiol alone or in combination with risedronate in 
men receiving antiandrogens [104]. Nonetheless, the 
importance of estradiol for male bone mass has raised 
the question as to whether selective estrogen receptor 
modulators (SERMs) could increase BMD in men 
receiving ADT for prostate cancer who develop low 
estradiol levels. One RCT has recently demonstrated that 
toremifene, a second-generation SERM, administered at 
a dose of 80 mg orally daily, is capable of: significantly 
increasing BMD at the lumbar spine, total hip and 
femoral neck versus placebo (p < 0.0001); decreasing 
bone turnover markers (p < 0.05); and, most importantly, 
reducing relative risk of new vertebral fractures by 
50% versus placebo in a 2 year period [105]. However, 
in addition to an improvement of lipid profile in the 
toremifene treated group, there was an increased rate of 
thromboembolic events with respect to the placebo group 
Figure 4: Assessment of fracture risk in countries with high access to DXA: FRAX-based assessment threshold (solid 
line) and FRAX-based intervention thresholds (dotted line) (reproduced from ref. 100).
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(2.6% versus 1.1%, respectively) [105]. Additional studies 
are therefore needed to better address the value of an 
estrogen replacement therapy in preserving and preventing 
bone loss and fragility fractures in men receiving ADT.
Since the loss of muscle mass and function represents 
a major problem in men receiving ADT, and increases the 
risk for fall and fractures, physical exercise with specific 
training programs and therapies addressing skeletal 
muscle might be advantageous for these patients [67]. 
Specific therapies targeting skeletal muscle, i.e. the anti-
myostatin antibody, have been tested in randomized trials, 
demonstrating that this treatment is effective in increasing 
muscle mass but not muscle function [106]. In this respect, 
selective androgen receptor modulators could be employed 
to maintain the favorable effects of androgens on muscle 
and bone while reducing undesirable side effects, as 
demonstrated by in vivo studies in animals [107, 108] and 
phase II trials in humans for skeletal muscle only [109]. 
However, RCTs are strongly needed, both in idiopathic 
osteoporosis and secondary osteoporosis, such as ADT-
induced bone and muscle loss, in order to make evidence-
based recommendations to decrease the risk of falls.
New therapies developed for the treatment of 
postmenopausal osteoporosis, such as the cathepsin K 
inhibitor odanacatib [110] and the antisclerostin antibody 
romosozumab [111], could be employed to control ADT-
mediated bone disease and decrease the risk for fragility 
fractures in such patients.
In addition to testing new drugs, a refinement of 
the intervention threshold in men with prostate cancer, 
which includes consideration of the age of the patients, is 
strongly advisable, as well as a validation of the FRAX in 
these subjects, considering competing mortality. Health-
economic studies on cost-effectiveness, particularly for 
denosumab, are needed in order to better inform regulatory 
agencies in identifying men at high risk for fracture 
undertaking ADT, for whom treatment is cost-effective 
or even cost-saving. Additional information on the size 
of the problem and the budget impact of antiresorptive 
prescriptions in each country is also required.
On the other hand, as recently demonstrated, 
significant gaps and barriers remain among prostate 
cancer specialists regarding the assessment, treatment 
and monitoring of bone disease in these patients, despite 
increased knowledge and awareness of the problem [112]. 
Multidisciplinary units, including bone experts, would be 
advisable in order to overcome barriers to care for and 
better identify at-risk subjects. Moreover, further studies 
assessing the specific impact of different ADT therapies 
and regimens on bone are needed, to better define and 
decrease the risk of fragility fractures.
CONCLUSIONS
Bone disease is a very common complication of ADT 
in men with hormone-sensitive advanced prostate cancer. 
The identification of high risk subjects is mandatory in order 
to select patients for taking advantage of antiresorptives 
in terms of BMD preservation and possible fracture risk 
reduction in the long term. The close collaboration of 
prostate cancer specialists and bone experts is pivotal for 
the development of shared guidelines for the management 
and monitoring of non-metastatic skeletal involvement, also 
taking into account cost-effectiveness analyses. 
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Table 2: Emerging therapies for the treatment of musculoskeletal consequences of androgen 
deprivation therapy
Agents targeting bone Agents targeting muscle
Chloride Channel Modulators Androgen Receptor Modulators (SARM)
Anti-cathepsin K GH Secretagogues
Anti-Integrins PPAR-beta Modulators
Src inhibitors Anti-Myostatin Antibodies
Androgen Receptor Modulators (SARM) Myostatin Soluble Receptors
GLP2 Anti-Activin II Receptors
Inhibitor of gut serotonin Angiotensin II Blockades
Anti-sclerostin Beta-2 Receptor Agonists
Anti-Dickkopf Anti-IL-6
Modulators of LRPs Pathway
Anti-activin Anti-activin
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